1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Discovery of the Genetic Basis of Childhood Cancers and of Congenital Anomalies: Gabriella Miller Kids First Pediatric Research Program (X01 Clinical Trial Not Allowed) is sponsored by National Institutes of Health (NIH). This program invites applications to sequence DNA samples from childhood cancer cohorts (and RNA samples from tumors) where a genetic basis is suspected but not yet identified, or where understanding recurring somatic mutations can address crucial questions in biology and therap…
Get alerted about grants like this
Get emailed when new opportunities from “National Institutes of Health (NIH)” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
## Gabriella Miller Kids First Pediatric Research (Kids First) The goal of the Gabriella Miller Kids First Pediatric Research Program (Kids First) is to help researchers uncover new insights into the biology of childhood cancer and congenital anomalies, including the discovery of shared genetic pathways between these disorders. Children with birth defects have an increased risk of developing childhood cancer.
This suggests there are shared genetic pathways underlying some types of childhood cancer and congenital anomalies. The Kids First program is in its second iteration, Kids First 2. 0, which continues to advance the groundwork laid in the program's first ten years.
Kids First is achieving this goal through two initiatives: 1) identifying children with childhood cancer and structural birth defects and their families for whole genome sequencing performed by the Kids First sequencing centers 2) developing theGabriella Miller Kids First Data Resource,")a large-scale database of clinical and genetic data from patients with childhood cancers and congenital anomalies and their families.
Analyzing genetic sequence data from children with childhood cancer and congenital anomalies together may lead to the discovery of new genetic pathways.
Clinical and genetic data from 36 of theKids First projectsare publicly available through theGabriella Miller Kids First Data Resource Portal"), a cloud-based platform made up of tools to foster analyses and collaborations between childhood cancer and congenital anomalies research communities. Kids First is enabling new findings in birth defects and childhood cancers.
For an overview of the Kids First Program watch the video below: **Kids First has over 36 Pediatric Cancer and Congenital Anomaly Datasets. ** Check it out at theKids First Data Resource Portal")! **Kids First Cloud Credits Pilot is Open to All Researchers!
** Cloud Credits are open and available to all researchers and sponsored by NIH. These credits enable researchers to conduct cloud-based analyses accessing Kids First data and utilizing the tools available through theKids First Data Resource Center"). The Cloud Credits program aims to lower barriers for using a web-based platform, building and sharing workflows, and analyzing Kids First and non-Kids First data in one cloud workspace.
If you would like to participate in the Kids First Cloud Credits Pilot, please read and follow the instructions described in the pilot announcement. Requests are submitted and reviewed on a rolling basis for quick access to cloud credits. If you have any questions, please contactKidsFirst@od.
nih. gov. Learn more about theKids First Cloud Credits Pilot Program. * Read the Gabriella Miller Kids First Research Act bill.
* NIH resources on Birth Defects: * Trans-NIH Structural Birth Defects Working Group * NIH resources on Childhood Cancers * Cancer Facts and Figures")from the American Cancer Society. Childhood cancers and structural birth defects have profound, lifelong effects on patients and their families.
A risk factor for childhood cancer is being born with a birth defect, suggesting there are shared genetic pathways underlying some types of childhood cancer and structural birth defects. However, there are limited data about shared pathways that may lead to the development of both outcomes.
The Kids First Data Resource will allow scientists to identify genetic pathways underlying these conditions and to explore some of these pathways are shared between them. These findings have the potential to improve prognostics and treatment decisions for childhood cancers. Clinical and genetic sequence data obtained through Kids First studies will be accessible to researchers everywhere through the Kids First Data Resource.
In 2015, Kids First selected seven cohorts of children with cancer or structural birth defects for whole genome sequencing. The DNA sequence data along with well-curated clinical phenotype data will be deposited into the forthcoming Kids First Data Resource. Genetic sequence and phenotype data from the Genomic Analysis of Congenital Diaphragmatic Hernia cohort is now publicly available.
Learn more about Kids First selected cohorts. ### The Gabriella Miller Kids First Data Resource Through its Data Resource Center and NIH X01 grant mechanism, Kids First supports data generation and data sharing in the cloud.
To date, the program has supported the public release of data from 37 projects and made available nearly 30,000 genomes, representing structural birth defects and childhood cancer patients and families through theKids First Data Resource Portal"). The following principal investigators were awarded access to sequence structural birth defects cohorts or childhood cancer cohorts at the Broad Institute's or St.
Jude Children’s Research Hospital/Hudson-Alpha Institute for Biotechnology's NIH supported sequencing center. The following principal investigators were awarded access to sequence structural birth defects cohorts or childhood cancer cohorts at the Broad Institute's or St. Jude Children’s Research Hospital/Hudson-Alpha Institute for Biotechnology's NIH supported sequencing center.
| RESNICK, ADAM CAIN (contact) CARROLL, ROBERT J DIGIOVANNA, JACK FERRETTI, VINCENT GROSSMAN, ROBERT L HAENDEL, MELISSA A HEATH, ALLISON TAYLOR, DEANNE MARIE VOLCHENBOUM, SAMUEL | CHILDREN'S HOSP OF PHILADELPHIA | Gabriella Miller Kids First Pediatric Data Resource Center: Advancing Collaborative Platform-Enabled Data-Driven Discovery at the Intersection of Childhood Development and Cancer | The following principal investigators were awarded access to sequence structural birth defects cohorts or childhood cancer cohorts at the Broad Institute's or St.
Jude Children’s Research Hospital/Hudson-Alpha Institute for Biotechnology's NIH supported sequencing center. The following principal investigators were awarded access to sequence structural birth defects cohorts or childhood cancer cohorts at the Broad Institute's or St. Jude Children’s Research Hospital/Hudson-Alpha Institute for Biotechnology's NIH supported sequencing center.
The following principal investigators were awarded access to sequence structural birth defects cohorts or childhood cancer cohorts at the Broad Institute's or St. Jude Children’s Research Hospital/Hudson-Alpha Institute for Biotechnology's NIH supported sequencing center.
| Whole Exome and Genome Sequencing in Structural Defects of the Neural Tube | The following principal investigators were awarded access to sequence structural birth defects cohorts or childhood cancer cohorts at the Broad Institute's or St. Jude Children’s Research Hospital/Hudson-Alpha Institute for Biotechnology's NIH supported sequencing center.
The following principal investigators were awarded access to sequence structural birth defects cohorts or childhood cancer cohorts at the Broad Institute's or St. Jude Children’s Research Hospital/Hudson-Alpha Institute for Biotechnology's NIH supported sequencing center. | RESNICK, ADAM CAIN (contact) DAVIS-DUSENBERY, BRANDI NICOLE FERRETTI, VINCENT GROSSMAN, ROBERT L.
HAKONARSON, HAKON KURAL, DENIZ MARGOLIN, ADAM ARNE STEIN, LINCOLN D TAYLOR, DEANNE MARIE VOLCHENBOUM, SAMUEL | CHILDREN'S HOSP OF PHILADELPHIA | Innovation through collaboration at the intersection of childhood development and cancer: a platform for the Gabriella Miller Kids First Pediatric Data Resource Center | The following principal investigators were awarded access to sequence structural birth defects cohorts or childhood cancer cohorts at the Broad Institute's or St.
Jude Children’s Research Hospital/Hudson-Alpha Institute for Biotechnology's NIH supported sequencing center. The following principal investigators were awarded access to sequence structural birth defects cohorts or childhood cancer cohorts at Baylor College of Medicine's or Washington University's NIH supported sequencing center.
Discovery of the Genetic Basis of Structural Birth Defects and of Childhood Cancers: Gabriella Miller Kids First Pediatric Research Program (X01).") This page last reviewed on June 15, 2026 Looking for U.S. government information and services? [](https://www.
nih. gov/common-fund/common-fund-programs/gabriella-miller-kids-first-pediatric-research-kids-first#)
According to the current listing, eligibility includes: Eligible applicants include various organization types, including nonprofits, state governments, public and state-controlled institutions of higher education, private institutions of higher education, independent school…. Confirm the full requirements in the official notice before applying.
Applications for Discovery of the Genetic Basis of Childhood Cancers and of Congenital Anomalies: Gabriella Miller Kids First Pediatric Research Program (X01 Clinical Trial Not Allowed) are due January 11, 2027. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Discovery of the Genetic Basis of Childhood Cancers and of Congenital Anomalies: Gabriella Miller Kids First Pediatric Research Program (X01 Clinical Trial Not Allowed) is funded by National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
NCI Continuing Umbrella of Research Experiences (CURE) Academic Career Excellence (ACE) Award (K32) is a grant from the National Cancer Institute (NCI) that funds early postdoctoral fellows from diverse backgrounds, including underrepresented groups, to pursue research training in cancer-related fields. The K32 award supports fellows within 12 months prior to transitioning into, or within the first two years of, a postdoctoral position. The program, operated through NCI's Center to Reduce Cancer Health Disparities (CRCHD), aims to enhance the pool of qualified diverse cancer researchers. Beginning with the June 12, 2025 due date, the CURE ACE Award is available in both Independent Clinical Trial Required and Independent Clinical Trial Not Allowed versions. Eligible applicants must be U.S. citizens or permanent residents at time of award.
Innovation Grant is a grant from the Delta Dental of Arizona Foundation that funds nonprofit organizations pursuing unique, high-impact projects that improve health and wellness in Arizona communities. This two-year award supports original initiatives with measurable real-world impact, including programs serving underserved and uninsured populations through oral health education, disease prevention, and nutritional access. Projects must demonstrate the potential to make a meaningful difference in the community and stand apart from conventional approaches. Eligible applicants are Arizona-based nonprofit organizations. Awards total $100,000 per recipient over two years. The 2026 application cycle closed October 16, 2025, with recipients notified in late 2025 and funding made available shortly after.
NIH's FY2026 budget held steady at $47.2 billion — yet by the end of February the agency had issued roughly 66% fewer competitive grant awards than its FY21–24 average, and by late spring award volume was still running dramatically below historical norms. The cause is not a budget cut. It is a pipeline failure: only 14 Notices of Funding Opportunity published by mid-March versus 756 in all of 2024, a workforce down nearly 20%, funds held by OMB into March, and new political-appointee sign-off on NOFOs. FY25 success rates fell to 17% — the lowest in 30 years — and early-stage investigators dropped to 18.5%. This is the definitive breakdown of what is happening, why the money isn't moving, and the concrete diversification strategy labs need for the next 18 months.
Read articleAfter an authorization lapse froze new SBIR/STTR awards for five months, NIH reopens its submission window on August 5, 2026, with a first standard deadline of September 8. Phase I awards run to $323,090, Phase II to $2,153,927, with published waiver topics reaching $700,000 and $3 million — and a new Phase IIB Strategic Breakthrough lane up to $30 million. Here is how the restarted omnibus is structured, why applying early matters more than usual this cycle, and how to position a life-science startup to win.
Read articleNIH has awarded 74% fewer new grants than its 2021-2024 average and is roughly $1 billion behind its normal timeline, but the FY2026 money still has to go out the door before the fiscal year ends. Here is why a year-end obligation cliff is coming, who is positioned to catch it, and how applicants should prepare for a compressed Q4 award rush.
Read article